Nanolongan with Multiple On-Demand Conversions for Ferroptosis-Apoptosis Combined Anticancer Therapy
文献类型:期刊论文
作者 | Bao, Weier1,2,3; Liu, Xianwu1,2,3; Lv, Yanlin2; Lu, Gui-Hong2; Li, Feng2; Zhang, Fan2; Liu, Bin1; Li, Dan1; Wei, Wei2; Li, Yuan1 |
刊名 | ACS NANO
![]() |
出版日期 | 2019 |
卷号 | 13期号:1页码:260-273 |
关键词 | Nanolongan Multiple On-demand Responsive Nir-responsive Ferroptosis Anticancer Combined Therapy |
ISSN号 | 1936-0851 |
DOI | 10.1021/acsnano.8b05602 |
英文摘要 | As a type of programmed cell death, ferroptosis is distinct from apoptosis. The combination of the two thus provides a promising modality with which to significantly improve anticancer treatment efficacy. To fully utilize this combination, we herein designed a nanolongan delivery system, which possessed a typical structure of one core (up-conversion nanoparticles, UCNP) in one gel particle (Fe3+ cross-linked oxidized starch) with multiple on-demand conversions. The charge conversion of the nanolongan surface in a slightly acidic microenvironment enhanced circulation time for utilizing the enhanced permeability and retention effect, enabled efficient uptake by tumor cells, and induced subsequently lysosomal escape. As the core component, the UCNP with light conversion from near-infrared light to ultraviolet impediment of limited penetration depth and enabled the reduction of Fe3+ to Fe2+. Accordingly, gel networks of nanolongan could be deconstructed due to this valence conversion, leading to the rapid release of Fe2+ and doxorubicin (Dox). In this case, the Fenton reaction between Fe2+ and intracellular H2O2 generated potent reactive oxygen species for ferroptosis, while the co-released Dox penetrated into nucleus and induced apoptosis in a synergistic way. As a result, superior anticancer therapeutic effects were achieved with little systemic toxicity, indicating that our nanolongan could serve as a safe and high-performance platform for ferroptosis apoptosis combined anticancer therapy. |
WOS关键词 | Prolonged Circulation ; Enhanced Permeability ; Nanoparticles ; Chemotherapy ; Cell ; Combination ; Trastuzumab ; Transition ; Insights ; Design |
资助项目 | National Natural Science Foundation of China[31471577] ; National Natural Science Foundation of China[31772014] ; National Natural Science Foundation of China[21622608] ; National Key R&D Program of China[2017YFA0207900] |
WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science |
语种 | 英语 |
WOS记录号 | WOS:000456749900026 |
出版者 | AMER CHEMICAL SOC |
资助机构 | National Natural Science Foundation of China ; National Key R&D Program of China |
源URL | [http://ir.ipe.ac.cn/handle/122111/27815] ![]() |
专题 | 中国科学院过程工程研究所 |
通讯作者 | Wei, Wei; Li, Yuan |
作者单位 | 1.China Agr Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Coll Food Sci & Nutr Engn, Key Lab Funct Dairy, Beijing 100083, Peoples R China 2.Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China 3.Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China |
推荐引用方式 GB/T 7714 | Bao, Weier,Liu, Xianwu,Lv, Yanlin,et al. Nanolongan with Multiple On-Demand Conversions for Ferroptosis-Apoptosis Combined Anticancer Therapy[J]. ACS NANO,2019,13(1):260-273. |
APA | Bao, Weier.,Liu, Xianwu.,Lv, Yanlin.,Lu, Gui-Hong.,Li, Feng.,...&Li, Yuan.(2019).Nanolongan with Multiple On-Demand Conversions for Ferroptosis-Apoptosis Combined Anticancer Therapy.ACS NANO,13(1),260-273. |
MLA | Bao, Weier,et al."Nanolongan with Multiple On-Demand Conversions for Ferroptosis-Apoptosis Combined Anticancer Therapy".ACS NANO 13.1(2019):260-273. |
入库方式: OAI收割
来源:过程工程研究所
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。